Rachael B. Turner, M.D., Ph.D.

Contact Information

Phone Numbers

Administrative: (585) 275-6759

Office: (585) 442-8020

Fax: (585) 442-8039

A member of the University of Rochester Medical Faculty Group

An Accountable Health Partner

Accepting New Patients

Locations

Lattimore Medical Center Oncology
125 Lattimore Rd, Ste 258
Rochester, NY 14620-4159

Oncology: (585) 442-8020

Faculty Appointments

Assistant Professor - Department of Medicine , Hematology/Oncology (SMD)
Assistant Professor - Department of Obstetrics and Gynecology (SMD) - Joint

Patient Care Setting

Cancer

Biography

Dr. Rachael Turner received her medical degree and her PhD from the University at Buffalo School of Medicine and Biomedical Sciences in 2013. Dr. Turner then completed her Internal Medicine Residency and Medical Oncology Fellowship at the University of Rochester Medical Center in 2015 and 2018, respectively. She is currently pursuing a Research Fellowship at the University of Rochester Medical Center. Dr. Turner is certified by the American Board of Internal Medicine.

Dr. Turner's special interests are women's cancers, including fallopian, ovarian, uterine and cervical. She is also interested in immune therapies for cancer. Dr. Turner is committed to providing personalized cancer care with compassion and dedication.

During her free time, Dr. Turner enjoys spending time with her husband and sons, running and hiking.

Credentials

Specialties

Internal Medicine - American Board of Internal Medicine
Medical Oncology - American Board of Internal Medicine

Education

2013
MD, PhD | SUNY at Buffalo School of Medicine and Biomedical Sciences

Post-doctoral Training & Residency

07/01/2015 - 07/19/2018
Fellowship in Medical Oncology at University of Rochester Medical Center

07/01/2014 - 06/30/2015
Residency in Internal Medicine at University of Rochester Medical Center

07/01/2013 - 06/30/2014
Internship in Internal Medicine at University of Rochester Medical Center

VIEW ALL

Awards

2018
Wilmot Fellowship Award
Sponsor: Wilmot Cancer Institute
Location: Rochester, NY

2018
Conquer Cancer Foundation/Women who Conquer Cancer- Young Investigator Award
Sponsor: Bristol-Myers Squibb
Location: ASCO

2017
Best Overall Poster Presentation for HE4 in Ovarian Cancer Immune Suppression Poster Presentation
Sponsor: James P. Wilmot Cancer Institute
Location: Rochester, NY

2011
Harold Brody Award for Translational Research
Sponsor: University of Buffalo
Location: Buffalo, NY

2010
Honorable Mention for poster presentation on Chronic Chemoimmunotherapy etc..
Sponsor: Buffalo Immunology
Location: Buffalo, NY

2009 - 2011
Breast Cancer Pre-doctoral Traineeship Award
Sponsor: Department of Defense

2005
Guy A. Bailey Outstanding Senior Award
Sponsor: SUNY Geneseo
Location: Geneseo, NY

2005
Phi Beta Kappa National Honor Society

2004
Tri-Beta Honor Society

VIEW ALL

Clinical Trials

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

Lead Researcher: Rachael B Turner

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

View Study Details

Publications

Journal Articles

2019
James NE, Oliver MT, Ribeiro JR, Cantillo E, Rowswell-Turner RB, Kim KK, Chichester CO, DiSilvestro PA, Moore RG, Singh RK, Yano N, Zhao TC. "Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6." Frontiers in pharmacology.. 2019 10:216. Epub 2019 Mar 19.

2018
James, N.E.; Cantillo, E. ;Oliver, M.T.; Rowswell-Turner, R.B. "HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells. Clin Exp Immunol. Epub ahead of print." 2018; .

2018
Rowswell-Turner R, Rutishauser J, Kim KK et al. "Novel small molecule MEK inhibitor URML-3881 enhances cisplatin sensitivity in clear cell ovarian cancer. Manuscript submitted for publication." 2018; .

VIEW ALL PUBLICATIONS